Medication-Assisted Treatment (MAT) for Opioid and Alcohol Addiction
Medication-assisted Treatment combines evidence-based medications with comprehensive medical and therapeutic support to help individuals recover from opioid and alcohol addiction. MAT reduces cravings, stabilizes withdrawal symptoms, and helps people sustain long-term recovery.
MAT for Opioid Addiction
Medication-assisted treatment for opioid use disorder involves the use of FDA-approved medications, including buprenorphine, methadone, and naltrexone, to help people reduce or stop their use of heroin, prescription painkillers, or other opioids.
Buprenorphine is a cornerstone of effective MAT for opioid addiction. Research shows that individuals attempting abstinence-only recovery face relapse rates exceeding 90% within the first year. By contrast, buprenorphine-based treatment (such as Suboxone® therapy) significantly improves the chances of sustained recovery.
Buprenorphine is an opioid medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of opioid use disorder. It can be prescribed and managed privately in a physician’s office, making it more accessible than methadone, which must be administered in a specialized clinic setting.
The combination buprenorphine/naloxone is found in several FDA-approved medications—including Suboxone®, Zubsolv®, and Bunavail®—and may be prescribed for take-home use in outpatient care. Buprenorphine acts as a partial opioid agonist, reducing cravings and withdrawal without producing the intense euphoria associated with full opioids such as heroin or oxycodone. Naloxone, included in many formulations, helps prevent misuse and blocks the effects of other opioids, lowering overdose risk.
Benefits of Buprenorphine Treatment
- Reduced cravings for opioids
- Diminished euphoria and physical dependence
- Relief from withdrawal symptoms
- Decreased use of illicit opioids
- Blocking the effects of other opioids
With successful buprenorphine (Suboxone®) treatment, many individuals regain control of their health and lives. Stabilizing withdrawal and reducing cravings allows patients to focus on rebuilding relationships, improving lifestyle patterns, and addressing emotional and psychological factors that support lasting recovery.
FDA-Approved Buprenorphine Medications
- Bunavail® (buprenorphine and naloxone) buccal film
- Cassipa® (buprenorphine and naloxone) sublingual film
- Probuphine® (buprenorphine) implant for subdermal administration
- Sublocade® (extended-release buprenorphine) injection for subcutaneous use
- Suboxone® (buprenorphine and naloxone) sublingual film or tablet
- Subutex® (buprenorphine) sublingual tablet
- Zubsolv® (buprenorphine and naloxone) sublingual tablets
MAT for Alcohol Addiction
Medication-Assisted Treatment for Alcohol Addiction can help individuals maintain sobriety after stopping alcohol use. Currently, there are only three FDA-approved medications for the treatment of alcohol dependence:
- Disulfiram
- Acamprosate
- Naltrexone
These medications are designed for individuals who have already stopped drinking and are working to maintain abstinence as part of their recovery process. They are not prescribed for individuals who are still actively drinking alcohol, and there are currently no medications available that cause people to stop drinking.
Each of these medications works differently—by reducing cravings, restoring brain chemistry balance, or creating deterrent effects—and can be used as part of an integrative treatment plan tailored to each person’s needs.